Omeros ROE 2009-2018 | OMER
Current and historical return on equity (ROE) values for Omeros (OMER) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Omeros ROE for the three months ending December 31, 2018 was 0.00%.
| Omeros ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $-0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $-0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| 2009-09-30 | $-0.02B | $-0.01B | 428.57% |
| 2009-06-30 | $-0.02B | $0.00B | inf% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.868B | $0.030B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $140.623B | 27.80 |
| Medtronic (MDT) | Ireland | $123.520B | 18.06 |
| Stryker (SYK) | United States | $73.875B | 27.09 |
| Boston Scientific (BSX) | United States | $52.874B | 25.78 |
| Baxter (BAX) | United States | $40.209B | 25.72 |
| Zimmer Biomet Holdings (ZBH) | United States | $26.486B | 16.96 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $17.634B | 0.00 |
| Canopy Growth (CGC) | Canada | $15.407B | 0.00 |
| ResMed (RMD) | United States | $14.469B | 27.44 |
| Aurora Cannabis (ACB) | Canada | $9.687B | 68.36 |
| Bio-Rad Laboratories (BIO) | United States | $9.455B | 53.94 |
| Hill-Rom Holdings (HRC) | United States | $7.140B | 22.08 |
| Perrigo (PRGO) | Ireland | $6.601B | 10.70 |
| Insulet (PODD) | United States | $6.039B | 2037.40 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $5.309B | 0.00 |
| ICU Medical (ICUI) | United States | $4.841B | 30.14 |
| Haemonetics (HAE) | United States | $4.496B | 39.88 |
| Hutchison China MediTech (HCM) | China | $3.961B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.830B | 0.00 |
| Neogen (NEOG) | United States | $3.332B | 51.18 |
| NuVasive (NUVA) | United States | $2.927B | 25.53 |
| Quidel (QDEL) | United States | $2.672B | 24.11 |
| Aphria (APHA) | $2.518B | 111.78 | |
| National Vision Holdings (EYE) | United States | $2.327B | 45.77 |
| HEXO (HEXO) | $1.429B | 0.00 | |
| Cardiovascular Systems (CSII) | United States | $1.402B | 1006.25 |
| Phibro Animal Health (PAHC) | United States | $1.308B | 18.80 |
| VAREX IMAGING (VREX) | United States | $1.299B | 25.44 |
| AtriCure (ATRC) | United States | $1.104B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.968B | 26.15 |
| MacroGenics (MGNX) | United States | $0.967B | 0.00 |
| Cerus (CERS) | United States | $0.885B | 0.00 |
| PetIQ (PETQ) | United States | $0.872B | 24.96 |
| NanoString Technologies (NSTG) | United States | $0.753B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.727B | 21.67 |
| OraSure Technologies (OSUR) | United States | $0.713B | 31.24 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.705B | 23.99 |
| Evolus (EOLS) | United States | $0.701B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.650B | 0.00 |
| Surmodics (SRDX) | United States | $0.618B | 89.94 |
| LeMaitre Vascular (LMAT) | United States | $0.614B | 29.21 |
| Quanterix (QTRX) | United States | $0.551B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.397B | 163.54 |
| Vapotherm (VAPO) | United States | $0.371B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.363B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.358B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.312B | 20.30 |
| Owens & Minor (OMI) | United States | $0.284B | 3.94 |
| Bovie Medical (APYX) | United States | $0.264B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.257B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.255B | 0.00 |
| Zynex (ZYXI) | United States | $0.143B | 15.35 |
| Fonar (FONR) | United States | $0.143B | 7.64 |
| Surface Oncology (SURF) | United States | $0.117B | 0.00 |
| Chimerix (CMRX) | United States | $0.102B | 0.00 |
| Female Health (VERU) | United States | $0.100B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.097B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.090B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.088B | 0.00 |
| United-Guardian (UG) | United States | $0.087B | 20.01 |
| CAS Medical Systems (CASM) | United States | $0.071B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.071B | 21.00 |
| Neurotrope (NTRP) | United States | $0.061B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.036B | 0.00 |
| Senestech (SNES) | United States | $0.028B | 0.00 |
| Myomo (MYO) | United States | $0.022B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.018B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.015B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 15.57 |
